Hear from Anshul Gupte Ph.D. RAC Drugs., a seasoned professional and Vice President of Pharmaceutical Development, as he shares valuable industry insights.
As Vice President of Pharmaceutical Development at PCI Pharma Services, my role includes supporting new business generation through thought and technical leadership. We can boost our existing capabilities by partnering with development teams throughout our global sterile fill-finish and oral development sites, offering end-to-end integrated drug product services.
As I picture the future of Drug Development and Manufacturing, I see AI-based tools taking the lead. These tools are poised to revolutionize the industry, accelerating drug discovery and significantly shortening the timeline for precision therapies to reach the market.
Targeted therapies, such as Targeted Protein Degraders (TPD), Nucleic acid-based therapies, and Antibody Drug Conjugates (ADC), are revolutionizing treatment options. To fulfill these promises, prefilled syringes, potent handling, and microemulsion systems such as nanoparticles, liposomes, etc., are expected to play an essential role.
By meeting our client partners’ needs with earlier engagement and science-driven solutions, our drug development and manufacturing business segment will evolve to offer upstream developability evaluation services for biologics and small molecules, which can link seamlessly to first-in-human, clinical development, and commercial services.
Agility, flexibility, and technical partnership will remain the hallmarks of our integrated end-to-end development, clinical and commercial manufacturing, and packaging services for innovative life changing therapies.
We are committed to supporting clients at every stage of the manufacturing cycle, delivering best-in-class services efficiently and effectively.
Find out more about our Speed Solutions.